Last reviewed · How we verify
CodaVax-RSV
At a glance
| Generic name | CodaVax-RSV |
|---|---|
| Sponsor | Codagenix, Inc |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children (PHASE1)
- Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CodaVax-RSV CI brief — competitive landscape report
- CodaVax-RSV updates RSS · CI watch RSS
- Codagenix, Inc portfolio CI